The accompanying table (click to enlarge or download) includes the 36 remaining companies in the ETF Innovators (ETFI) Emerging Bio-Pharma Index with market caps between $150M-$1.5B, which were not included in the previous two articles I wrote about the group – featuring the Top 40 Rated Companies and companies below the $150M market cap cutoff.

However, several of the companies included in the remaining group of 36 have been in the news recently due to FDA related news. Late last week, Ligand Pharma (LGND) received approval along with its collaboration partner Glaxo (GSK) for Promacta while Theravance (THRX) received a positive panel review for its antibiotic telavancin. Previously, Amag Pharma (AMAG) more than doubled on word the FDA would decide on its iron-deficiency anemia drug ferumoxytol by year-end.

Last Friday, Dyax Corp. (DYAX) reported that the FDA accepted its BLA with a priority review for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) with a decision date deadline in late March 2009. Savient Pharma (SVNT) expects to hear back from the FDA on its Puricase BLA before year-end on whether the agency will accept the application and designate it as a six-month priority review.

Human Genome Sciences (HGSI) is due to release Phase 3 results before year-end for hepatitis C drug Albuferon with the stock trading near all-time lows below 2 bucks and far from the triple digit share price achieved during the biotech madness around the year 2000 – check out this Seeking Alpha article for a summary of the situation since I do not follow the stock.

Alnylam (ALNY) is trading well off its highs by about 50% at near two-year lows with a bullish outlook based on its RNA interference (RNAi) drug discovery platform and extensive early stage pipeline, which Merck (MRK) paid $1.1B two years ago for a similar RNAi drug discovery company, Sirna Therapeutics.